Drug review: Carfilzomib

Carfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here.

Saved in:
Bibliographic Details
Main Author: Prasanth Ganesan
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=130;epage=131;aulast=Ganesan
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850104955480834048
author Prasanth Ganesan
author_facet Prasanth Ganesan
author_sort Prasanth Ganesan
collection DOAJ
description Carfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here.
format Article
id doaj-art-40b6ca00a8214b2eadc539ab64641624
institution DOAJ
issn 0971-5851
0975-2129
language English
publishDate 2019-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series Indian Journal of Medical and Paediatric Oncology
spelling doaj-art-40b6ca00a8214b2eadc539ab646416242025-08-20T02:39:13ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292019-01-0140113013110.4103/ijmpo.ijmpo_67_19Drug review: CarfilzomibPrasanth GanesanCarfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=130;epage=131;aulast=GanesanCarfilzomibproteasome inhibitormultiple myeloma
spellingShingle Prasanth Ganesan
Drug review: Carfilzomib
Indian Journal of Medical and Paediatric Oncology
Carfilzomib
proteasome inhibitor
multiple myeloma
title Drug review: Carfilzomib
title_full Drug review: Carfilzomib
title_fullStr Drug review: Carfilzomib
title_full_unstemmed Drug review: Carfilzomib
title_short Drug review: Carfilzomib
title_sort drug review carfilzomib
topic Carfilzomib
proteasome inhibitor
multiple myeloma
url http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=130;epage=131;aulast=Ganesan
work_keys_str_mv AT prasanthganesan drugreviewcarfilzomib